• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    2/13/24 4:34:49 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PLUR alert in real time by email
    SC 13G/A 1 ea193604-13ga2shayna_pluri.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    (Amendment No. 2)

     

    Under the Securities Exchange Act of 1934

     

    PLURI INC.

    (Name of Issuer)

     

    Common Shares, par value $0.00001 per share

    (Title of Class of Securities)

     

    72942G 104

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 2 of 10 Pages

     

    1.

    Names of Reporting Persons

     

    Shayna LP(1)

    2.

    Check the Appropriate Box if a Member of a Group

     

    (See Instructions)

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,354,058 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,354,058(2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,354,058(2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    (See Instructions)  

    ☐
    11.

    Percent of Class Represented by Amount in Row (9)

     

    8.1%(3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1) Carmel Argaman Investments Ltd. (“Carmel”) is the general partner of Shayna LP. As of September 27, 2023, Avraham Levin Holdings Ltd., a company incorporated under the laws of the state of Israel, which is wholly owned by Mr. Avraham Levin, is the sole shareholder of Carmel following a transfer of shares agreement between Guy David Shantser and Avraham Levin Holdings Ltd. Shayna LP, Carmel, Avraham Levin Holdings Ltd., and Mr. Avraham Levin are collectively referred to as the “Reporting Persons”.
       
    (2) As of December 31, 2023, Shayna LP is the beneficial owner of 3,354,058 Common Shares, par value $0.00001 per share (“Common Shares”) of Pluri Inc. (the “Issuer”), and warrants to purchase up to 3,599,621 Common Shares exercisable within 60 days of December 31, 2023, granted to Shayna LP pursuant to a Common Stock Purchase Warrant. Pursuant to the Common Stock Purchase Warrant, Shayna LP shall not have the right to exercise the warrants to the extent that after giving effect to issuance of Common Shares following such exercise, Shayna LP, would beneficially own in excess of 4.99% of the number of Common Shares outstanding.
       
    (3) Based on a total of 41,480,172 Common Shares outstanding as of November 13, 2023, as reported in the Quarterly Report on Form 10-Q of the Issuer filed with the Securities and Exchange Commission (the “SEC”), on November 13, 2023.

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 3 of 10 Pages

     

    1.

    Names of Reporting Persons

     

    Carmel Argaman Investments Ltd.

    2.

    Check the Appropriate Box if a Member of a Group

     

    (See Instructions)

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,354,058 (1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,354,058(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,354,058

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    (See Instructions)  

    ☐
    11.

    Percent of Class Represented by Amount in Row (9)

     

    8.1%

    12.

    Type of Reporting Person (See Instructions)

     

    CO

      

    (1)As of December 31, 2023, Carmel is the beneficial owner of warrants to purchase up to 291,262 Common Shares exercisable within 60 days of December 31, 2023, granted to Carmel pursuant to a Common Stock Purchase Warrant. Pursuant to the Common Stock Purchase Warrant, Carmel shall not have the right to exercise the warrants to the extent that after giving effect to issuance of Common Shares following such exercise, Carmel, would beneficially own in excess of 4.99% of the number of Common Shares outstanding.

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 4 of 10 Pages

     

    1.

    Names of Reporting Persons

     

    Avraham Levin Holdings Ltd.

    2.

    Check the Appropriate Box if a Member of a Group

     

    (See Instructions)

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,354,058 (1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,354,058(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,354,058

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    (See Instructions)  

    ☐
    11.

    Percent of Class Represented by Amount in Row (9)

     

    8.1%

    12.

    Type of Reporting Person (See Instructions)

     

    CO

      

     

     

     

    CUSIP No. 72942G 104 13G/A Page 5 of 10 Pages

     

    1.

    Names of Reporting Persons

     

    Avraham Levin

    2.

    Check the Appropriate Box if a Member of a Group

     

    (See Instructions)

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,354,058

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,354,058

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,354,058

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    (See Instructions)  

    ☐
    11.

    Percent of Class Represented by Amount in Row (9)

     

    8.1%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

      

     

     

     

    CUSIP No. 72942G 104 13G/A Page 6 of 10 Pages

     

    This Amendment No. 2 to Schedule 13G (this “Schedule 13G/A”) amends and supplements the Schedule 13G initially filed with the SEC on February 16, 2023 (the “Schedule 13G”) by Shayna LP, a limited partnership organized under the laws of the Cayman Islands, and the Schedule 13G/A filed with the SEC on September 15, 2023.

     

    Item 1(a). Name of Issuer

     

    This item is not being amended by this Schedule 13G/A.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices

     

    This item is not being amended by this Schedule 13G/A.

     

    Item 2(a). Name of Person Filing

     

    This item is amended and restated by this Schedule 13G/A as follows:

     

    This Schedule is filed on behalf of each of the following Reporting Persons:

     

    Shayna LP, a limited partnership organized under the laws of the Cayman Islands.

     

    Carmel, a company organized under the laws of the State of Israel. Carmel serves as the general partner of Shayna LP.

     

    Avraham Levin Holdings Ltd., a company organized under the laws of the State of Israel. Avraham Levin Holdings Ltd. is the sole shareholder of Carmel.

     

    Avraham Levin, a citizen of the State of Israel. Avraham Levin is the sole shareholder of Avraham Levin Holdings Ltd.

     

    Item 2(b). Address of Principal Business Offices or, if None, Residence

     

    The address of each Reporting Person is:

     

    Shayna LP

    CO Services, P.O. Box 10008

    Willow House, Cricket Square

    Grand Cayman, KY1-1001

    Cayman Islands

     

    Carmel

    34 Kahal Street

    Meitar, Israel 8502500

     

    Avraham Levin Holdings Ltd.

    34 Kahal Street

    Meitar, Israel 8502500

     

    Avraham Levin

    34 Kahal Street

    Meitar, Israel 8502500

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 7 of 10 Pages

     

    Item 2(c). Place of Organization.

     

    This item is amended and restated by this Schedule 13G/A as follows:

     

    Shayna LP is organized under the laws of the Cayman Islands.

     

    Carmel is organized under the laws of the State of Israel.

     

    Avraham Levin Holdings Ltd. is organized under the laws of the State of Israel.

     

    Avraham Levin is a citizen of the State of Israel.

     

    Item 2(d). Title of Class of Securities

     

    This item is not being amended by this Schedule 13G/A.

      

    Item 2(e). CUSIP Number

     

    This item is not being amended by this Schedule 13G/A. 

     

    Item 3. If the statement is being filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the filing person is a:

     

    This item is not being amended by this Schedule 13G/A.

     

    Item 4. Ownership

     

    This item is amended and restated by this Schedule 13G/A as follows:

     

    (a) Amount beneficially owned:

     

    Each of the Reporting Persons is deemed to beneficially own 3,354,058 shares of the Issuer’s Common Shares and warrants to purchase up to 3,599,621 Common Shares exercisable within 60 days of December 31, 2023, granted to Shayna LP pursuant to a Common Stock Purchase Warrant. Pursuant to the Common Stock Purchase Warrant, Shayna LP shall not have the right to exercise the warrants to the extent that after giving effect to issuance of Common Shares following such exercise, Shayna LP would beneficially own in excess of 4.99% of the number of Common Shares outstanding.

     

    (b) Percent of class:

     

    Shayna LP, Carmel, Avraham Levin Holdings Ltd., and Mr. Avraham Levin – 8.1%

     

    (c) Number of shares as to which each of the Reporting Persons has:

     

    (i)   Sole power to vote or to direct the vote: 0

     

    (ii)   Shared power to vote or to direct the vote: 3,354,058

     

    (iii)   Sole power to dispose or to direct the disposition of: 0

     

    (iv)   Shared power to dispose or to direct the disposition of: 3,354,058

     

    (1)Based on a total of 41,480,172 Common Shares outstanding as of November 13, 2023, in the Quarterly Report on Form 10-Q of the Issuer filed with the SEC on November 13, 2023.

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 8 of 10 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    This item is not being amended by this Schedule 13G/A.

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person 

     

    This item is not being amended by this Schedule 13G/A.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    This item is not being amended by this Schedule 13G/A.

     

    Item 8. Identification and Classification of Members of the Group

     

    This item is not being amended by this Schedule 13G/A.

     

    Item 9. Notice of Dissolution of Group

     

    This item is not being amended by this Schedule 13G/A.

     

    Item 10. Certification

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 9 of 10 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each Reporting Person certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2024  
      SHAYNA LP

     

      By: Carmel Argaman Investments Ltd., general partner

     

      By: /s/ Avraham Levin
      Name:  Avraham Levin
      Title: Sole Shareholder

      

      CARMEL ARGAMAN INVESTMENTS LTD.

      

      By: /s/ Avraham Levin
      Name:  Avraham Levin
      Title: Sole Shareholder

     

      AVRAHAM LEVIN HOLDINGS LTD.

     

      By: /s/ Avraham Levin
      Name:  Avraham Levin

     

      AVRAHAM LEVIN

     

      By: /s/ Avraham Levin
      Name:  Avraham Levin

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

     

    CUSIP No. 72942G 104 13G/A Page 10 of 10 Pages

     

    EXHIBIT INDEX

     

    Exhibit   Description
    99.1   Agreement of Joint Filing, dated as of February 13, 2024, by and among the Reporting Persons.

     

     

     

     

     

     

    Get the next $PLUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLUR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

      Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal year 2025 compared to the same period in fiscal year 2024, driven by its CDMO and AgTech businesses, and is advancing new food tech partnerships and licensing opportunities HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today issued the following shareholder update from Chief Executive Officer an

      5/15/25 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DarioHealth Announces CFO Transition

      NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity. "It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished,

      4/21/25 8:30:00 AM ET
      $BNRG
      $DRIO
      $PLUR
      Building Products
      Industrials
      Medical/Dental Instruments
      Health Care
    • Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel

      Latest granted patents reinforce Pluri's position as a leader in Mucosal-Associated Invariant T ("MAIT") cell-based cell therapies for solid cancersPluri's MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, "off-the-shelf" therapy for cancer patientsPluri's MAIT platform addresses the global immune cell engineering market, projected to reach approximately $11.7 billion by 2030, and the global cancer immunotherapy market, calculated at $136 billion in 2025In addition to MAIT cells, Pluri's platform also supports the expansion of Tumor Infiltrating Lymphocytes (TILs), further broadening the scope of potential immune cell ther

      4/10/25 8:30:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pluri Inc.

      10-Q - Pluri Inc. (0001158780) (Filer)

      5/13/25 4:03:23 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Inc. filed SEC Form 8-K: Other Events

      8-K - Pluri Inc. (0001158780) (Filer)

      5/8/25 8:30:07 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Inc. filed SEC Form 8-K: Shareholder Director Nominations

      8-K - Pluri Inc. (0001158780) (Filer)

      4/29/25 4:00:31 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Financials

    Live finance-specific insights

    See more
    • BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

      Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil

      11/11/24 6:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shemesh-Rasmussen Maital was granted 11,173 shares, increasing direct ownership by 154% to 18,445 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:19 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Levi Rami Avraham was granted 11,173 shares, increasing direct ownership by 156% to 18,314 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:22 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Zalts Liat was granted 67,857 shares, increasing direct ownership by 319% to 89,107 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:17 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Leadership Updates

    Live Leadership Updates

    See more
    • Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

      HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of

      3/6/24 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

      HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023.  Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t

      7/13/23 2:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      2/13/24 4:34:49 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      2/1/24 4:02:29 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      9/15/23 4:00:03 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care